On September 8, 2023 ProMIS Neurosciences Inc. (Nasdaq: PMN) ("ProMIS" or the "Company"), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), reported that it closed its previously announced private investment in public equity ("PIPE") financing, for the issuance and sale of common share units, each consisting of one of the Company’s common shares (the "Common Shares") and one warrant to purchase one Common Share (the "Warrants") (the "Common Share Units") and pre-funded units, each consisting of one pre-funded warrant to purchase one Common Share and one Warrant (Press release, ProMIS Neurosciences, SEP 8, 2023, View Source [SID1234635033]). The Common Share Units were sold at a price of $1.88 per unit and the Pre-Funded Warrants were sold at a price of $1.87 per unit for gross proceeds of approximately $20.4 million, before deducting fees to the placement agents and other offering expenses payable by the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from the PIPE financing will be used to advance the clinical development of PMN310, ProMIS’ lead therapeutic candidate, as well as for working capital and other general corporate expenses.

BTIG, LLC acted as the placement agent for this offering.

The offer and sale of the foregoing securities were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended ("Securities Act"), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. ProMIS Neurosciences has agreed to file a registration statement with the SEC registering the resale of the Common Shares and the Common Shares issuable upon the exercise of the Pre-Funded Warrants and Warrants issued in the PIPE financing.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or other jurisdiction.

On September 8, 2023 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported the grants of inducement restricted stock units ("RSUs") to 11 new employees, as well as options ("Options") to one of the new employees, in connection with their employment with UroGen (Press release, UroGen Pharma, SEP 8, 2023, View Source [SID1234635032]). These new team members will support the ongoing commercial launch of Jelmyto (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the continued development of the Company’s pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Up to 37,300 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs and up to 30,000 ordinary shares are issuable upon the vesting and exercise of the Options. The Options have an exercise price of $17.94 per share, which was the closing price of the ordinary shares on September 6, 2023, the date of grant, as reported on The Nasdaq Stock Market. The RSUs and Options will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.

The RSUs and Options are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU and Option grant notice and agreements thereunder. The RSUs and Options were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq listing Rule 5635(c)(4).

On September 8, 2023 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company’s strategy, performance and the latest market developments and trends during a fireside chat at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023, at 2:00 p.m. Eastern Time (Press release, Quest Diagnostics, SEP 8, 2023, View Source [SID1234635031]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation and Q&A session will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until October 13, 2023.

On September 8, 2023 Portage biotech presented its corporate presentation (Presentation, Portage Biotech, SEP 8, 2023, View Source [SID1234635030]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 8, 2023 PharmaMar (MSE:PHM) reported five abstracts to be presented at the IASLC World Lung Cancer Congress 2023 on its compound Zepzelca (lurbinectedin) (Press release, PharmaMar, SEP 8, 2023, View Source [SID1234635029]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among the most important studies to be made public are the following: "Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial". Patients with platinum-sensitive, relapsed Small Cell Lung Cancer (SCLC) who received platinum re-challenge immediately after lurbinectedin + doxorubicin showed longer survival compared to those who received it after topotecan/CAV, thereby suggesting that giving lurbinectedin as second line to platinum-sensitive, relapsed SCLC patients does not affect the efficacy of subsequent platinum re-challenge and could extend the platinum-free interval and improve patient survival.

"Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients". These results suggest that lurbinectedin may effectively extend the platinum-free interval while maintaining the possibility of platinum re-challenge, leading to improved outcomes for patients with relapsed SCLC.

As part of the conclusion of the last two posters, Dr Ali Zeaiter, VP and Head of Clinical Development at PharmaMar says: "the effect of platinum re-challenge after lurbinectedin given as monotherapy or in combination with doxorubicin is similar to that previously reported with platinum re-challenge as second line therapy in platinum-sensitive patients (Baize et al., 2020). This supports that lurbinectedin is an alternative second line treatment option to platinum re-challenge for patients with platinum-sensitive relapsed SCLC".

"Effectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Data Study". The safety and effectiveness outcomes of lurbinectedin in relapsed Small Cell Lung Cancer (SCLC) in the real world were generally consistent with those seen in the phase II trial. In addition, the rates of neutropenia, thrombocytopenia, anemia and febrile neutropenia tended to be lower than what was observed in the basket trial.

"Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis." The study continues to enroll a broader population of SCLC patients than the collective Phase II trial that supported FDA approval. The real-world safety profile of lurbinectedin in this analysis was generally consistent with those reported in the collective trial, with no new safety events. The prophylactic use of G-CSF likely contributed to the low rates of neutropenia reported.

Lurbinectedin’s abstracts at the IASCL 2023 World Lung Cancer Congress
PRODUCT TITLE LEAD AUTHOR ABSTRACT
Zepzelca (lurbinectedin) Effectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer A.K. Ganti ABSTRACT: P2.17-02 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial Alejandro Navarro ABSTRACT: P2.17-06 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis B. Halmos ABSTRACT: P2.17-07 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients J.M Trigo ABSTRACT: EP13.07-06 POSTER SESION: Small Cell Lung Cancer and Neuroendocrine Tumors – Relapse and Salvage Therapy
Cost- Effectiveness Modeling of Lurbinectedin As a Second-line Therapy in Patients with Small Cell Lung Cancer Wayne Su